ArticleCase reports in medicine2026
Pediatric Sarcoidosis With Chronic Massive Splenomegaly and Renal Involvement: A Case Report.
Article in Case reports in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pediatric Sarcoidosis With Chronic Massive Splenomegaly and Renal Involvement: A Case Report.Case reports in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Systemic sarcoidosis is a rare multisystem rheumatologic disorder that is diagnosed after ruling out other granulomatous diseases. Clinical manifestations and treatment in these pediatric patients are also a challenge. Treatment is typically based on corticosteroids and cytotoxic agents; however, no organ-specific treatment currently exists. Recent studies have demonstrated the effectiveness of anti-TNF drugs in treating pulmonary and extrapulmonary sarcoidosis. Case Presentation: We report the case of a 16-year-old boy who, since the age of 12, presented with cytopenia, constitutional symptoms, and abdominal pain without a definitive diagnosis. At Age 16, he developed massive splenomegaly with lung and renal involvement. A diagnosis of systemic sarcoidosis was confirmed via a spleen biopsy. He was treated with infliximab in combination with corticosteroids and a cytotoxic agent. Conclusion: This report emphasizes the importance of diagnosing sarcoidosis based on rare and nonspecific signs and symptoms and treatment choices. Early diagnosis of this disease can lead to more effective treatment and prevent multiple organ involvement. Although there is not any organ-specific treatment for systemic sarcoidosis in children, with just a few reports of effectiveness of infliximab in kidney involvement, we decided to treat our case with infliximab because of corticosteroid and cytotoxic failure. This treatment may show that infliximab plays a key role in treating corticosteroid-resistant sarcoidosis that affects certain organs, like the kidneys, or in reducing the side effects of corticosteroid drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.